Duchenne muscular dystrophy (DMD)

PTC notches up full house of failures in CF with ataluren, dumps program

Catabasis routed after DMD trial failure

Catabasis lifted by early-stage muscular dystrophy data, but bigger test is coming soon

Sarepta jumps on J.P. Morgan update, gene therapy DMD deals

Shortened telomeres linked to heart damage in Duchenne muscular dystrophy

FDA expert lashes out at 'worrisome' Sarepta approval in JAMA

Small cap PTC tumbles as FDA rejects it again in Duchenne

Summit, Sarepta in $584M-plus DMD pipeline license pact in Europe